Stockbroker

COLORADO SPRINGS, Colo., Sept. 9, 2010 (CRWENEWSWIRE) — Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials.

See: http://abcnews.go.com/Business/medical-marijuana-commercial-airs-california/story?id=11547326

“It is a matter of record within the medical community that medical marijuana can have positive results in helping relieve nausea and vomiting among cancer patients receiving chemotherapy and increasing appetites among AIDS patients,” Mike Armstrong, acting general manager of KTXL in Sacramento, said in a statement e-mailed to FOX40.com, alluding that the ad is no different from that of any medicine advertised by pharmaceutical companies on local television channels and cable networks for decades.

See: http://www.fox40.com/news/headlines/ktxl-news-potad0830,0,5605124.story

Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, “The FOX40 ad sets a new milestone for general public acceptance of medical cannabis. Centuries of knowledge record that cannabis is an efficacious medicinal treatment for a host of ailments, yet governments continues to cling to clouded ideologies against this natural medicine and instead support man-made pharmaceuticals that often produce more harm than medicinal good. We are optimistic that the unique holistic value of medical cannabis, with its ability to supplement our natural endocannabinoid system will continue to spread throughout the country and the world. Dispensaries currently lead the way throughout California and other U.S. states, such as Colorado where our licensed dispensary is located. The Company sees this as an opportune time to expand the marketing of its products and licensing dispensaries. We look forward to future TV marketing campaigns for Cannabis Science products and our licensed RockBrook dispensary.”

Richard Cowan, Cannabis Science CFO, added, “We are encouraged that mainstream media is accepting medical cannabis dispensary advertisements in California, which is opening the door for us to expand the advertisement of our own licensed dispensary and products. On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired the first ever-paid U.S. television ad for a medical cannabis dispensary on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. From a marketing perspective, this is a huge leap forward in giving medical cannabis dispensaries the opportunities that chemically manufactured medicines have long held.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:

Cannabis Science, Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Friedman
1-877-431-CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com

********************************************************************

CRWEnewswire is not liable for the contents of this news, as well as not being liable for any errors or delays in the content, or for any actions taken in reliance thereon.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB)

LAS VEGAS, Sept. 9, 2010 (CRWENEWSWIRE) — EQ Labs, Inc. (EQLB.PK) announced today that it closed a deal with Terrible Herbst Corporation to place EQ Energy Drink in 108 Terrible Herbst convenience stores effective immediately. As a result of this closing, EQ Labs expects to receive a large commercial order for its energy drink to stock all 108 Terrible Herbst stores within the next 30 days.

Terrible Herbst Corporation owns and operates gas stations and convenience stores in Nevada, California, Utah and Arizona. It also engages in operating car wash facilities, casinos, hotels, parks, slot routes, and motor sports, as well as in car lube and detail operations. The company was founded in 1937 and is based in Las Vegas, Nevada.

Many of the Terrible Herbst convenience stores are located in Chevron gas stations with point of purchase advertising displays. As a result of the closing of this deal with Terrible Herbst, EQ Labs will also receive point of purchase advertising at over 100 stores.

Mo Owens, Chief Executive Officer of EQ Labs, stated, “This order is confirmation of the popularity of EQ. We have spent a lot of time and energy building our brand. This order provides the economic benefit of a large order. In addition, the advertising opportunity and the desired location of many of Terrible Herbst’s locations will place our product line in front of millions of potential customers. “

Owens added, “This deal would not be possible without the help of Mark Walters and Rio Valentino. Mark Walters, Director of Merchandising and Sales for Terrible Herbst is an expert in the sales and merchandising business. We are also consummating a relationship with a major distributor as a result of Mark’s extensive relationships. I also can’t forget Rio Valentino, our Vice President of Sales. Rio’s persistence and skills is one of the biggest reasons why are sales are beginning to accelerate and we hope to make many more announcements like this one over the near future. This is a very big moment for our company.”

About EQ Labs, Inc. EQ Labs is engaged in the development, marketing and sale of EQ (”The Smart Energy Drink”). EQ is an effervescent tablet that can be dissolved in any beverage to provide instant energy. Consisting of a blend of essential vitamins, Gingko Biloba, and less caffeine than a cup of coffee. EQ is currently sold at Best Buy, 7-Eleven, Walgreens and other leading retailers. For more information about EQ, visit: http://www.drinkeq.com/.

Forward-Looking Statements: This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by EQ Labs, Inc. are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact:

EQ Labs, Inc.
Maurice “Mo” Owens, CEO
702-445-7762
Fax: 702-445-7762
mo@drinkeq.com
Bob Fain, COO
bob@drinkeq.com

********************************************************************

CRWEnewswire is not liable for the contents of this news, as well as not being liable for any errors or delays in the content, or for any actions taken in reliance thereon.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK)